相关实验视频
Updated: Jun 6, 2025

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.8K
激活GPCR,ORL1受体:一种新的治疗方法,可以预防心力衰竭的进展
Saliha S Pathan1, Aarthi Pugazenthi1, Beverly R E A Dixon1
1Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Journal of cardiovascular development and disease
|November 26, 2024
概括
用MCOPPB激活ORL1受体显著改善了心脏功能,并在缺血性心力衰竭的老鼠模型中减少了纤维化. 这表明MCOPPB可能是预防心力衰竭进展的新疗法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 缺血性心力衰竭 (HF) 是一个日益严重的全球健康问题,目前没有预防性治疗方法.
- 之前的研究表明,Gata4的过度表达改善了心肌梗塞 (MI) 后的心脏功能,并提高了内源ORL1受体连接体Pnoc基因的调节.
- 这项研究研究了ORL1受体激活在缺血性HF模型中的治疗潜力.
研究的目的:
- 测试ORL1受体激活在老鼠缺血性心脏模型中抑制HF进展的假设.
- 评估ORL1激活剂MCOPPB在改善心脏功能和心脏后心脏病重塑方面的疗效.
主要方法:
- 成年Sprague Dawley大鼠接受了冠状动脉绑定以诱导心肌梗塞.
- 在绑定后,大鼠接受了盐水或MCOPPB (ORL1激活剂) 的腹腔内注射,持续3个月.
- 用心声扫描来评估心脏功能,并在组织学上分析心脏纤维化和血管生成.
主要成果:
- 与盐水对照组相比,MCOPPB治疗显著改善了患有缺血性HF的老鼠的射出分数 (67%与43%相比,p <0.001).
- 组织学分析显示,MCOPPB减少了心脏纤维化,促进了血管生成.
- 这些发现表明ORL1激活对心脏梗塞的保护作用.
结论:
- 使用MCOPPB激活ORL1受体显示出缓解心脏功能障碍和心肌梗塞后重塑的显著治疗潜力.
- MCOPPB可能是预防缺血性心力衰竭进展的新药学策略.
- 准ORL1受体为未来的心力衰竭治疗提供了一个有希望的途径.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
G-Protein Gated Ion Channels
4.5K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
4.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
GPCR Desensitization
5.8K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.8K
Transducer Mechanism: G Protein–Coupled Receptors
1.8K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
1.8K

